Single-fraction SABR matched multi-fraction outcomes in early-stage NSCLC
In 778 patients, single-fraction SABR showed similar local failure, survival and toxicity to three- or four-fraction treatment.
Tag
SABR
Online adaptation preserved kidney SABR coverage, but daily anatomical effects were small
Adaptation preserved prescription-level D99 in all 50 fractions, while a 1-mm margin achieved 98% despite minimal daily dose perturbation.
SABR controls oligometastatic breast lesions well, but systemic benefit remains uncertain
SABR achieved 92.5% one-year local control in oligometastatic breast cancer, while pooled randomized evidence did not definitively establish a PFS benefit.
PSMA/MRI-guided prostate SABR with focal boost showed strong two-year imaging response
In ARGOS-CLIMBER, PSMA/MRI-guided five-fraction pelvic SABR produced a 67% PET complete response rate at two years with limited late GU toxicity.
Bone SABR preserved quality of life through one year in BONY-M
Quality of life remained stable after 30–37.5 Gy in three fractions, while symptomatic patients achieved 59% pain response at 24 weeks.
Dose accumulation was feasible for toxicity assessment in MR-guided abdominal SABR
Accumulated gastrointestinal doses were generally lower than planned, while higher small-bowel dose showed exploratory associations with diarrhoea after MR-guided SABR.
Daily skin variation caused substantial target underdose in kidney proton SABR
Daily surface changes shifted proton beam depth by up to 17.4 mm and reduced accumulated target D99 by up to 24.3%.
Early PSA-density kinetics after prostate SABR identified patients at high recurrence risk
Combining ISUP grade with 3–6-month PSA-density kinetics separated seven-year biochemical control at 93.5% versus 53.4% after SABR without ADT.
Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Earlier lung cancer diagnosis exposed major delays in curative radiotherapy access
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Prostate SABR practice varied despite broad adoption across Australia and New Zealand
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Small gastrointestinal PRV margins limited dose increases but did not encompass pancreatic SABR motion
Two- to five-millimetre gastrointestinal margins usually limited delivered dose increases but frequently failed to encompass interfraction organ motion.
Consolidative and salvage primary-tumour SABR showed similar outcomes in stage IV NSCLC
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.
Posterior tumour drift threatens lung stereotactic ablative radiotherapy target coverage
In free-breathing lung stereotactic ablative radiotherapy, posterior drift exceeded the 4-millimetre margin in 15.7% of patients within 20 minutes.